Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 3/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | GRK2 | P25098 | 1/20 | 0.48 |
| ▸ | GRK3 | P35626 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907788 | 1.00 | HDAC8 (0.52) | HDAC8NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4907770 | 1.00 | HDAC8 (0.52) | HDAC8NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4910489 | 0.86 | SMN1; SMN2 (0.56) | HDAC8NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4910470 | 0.86 | SMN1; SMN2 (0.56) | HDAC8NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4910494 | 0.86 | SMN1; SMN2 (0.56) | HDAC8NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL684482 | 0.82 | KDM1A (0.61) | HDAC8NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1669378 | 0.80 | KMT2A (0.68) | HDAC8MAPTSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL1669374 | 0.80 | KMT2A (0.68) | HDAC8MAPTSMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL5809141 | 0.79 | GAA (0.65) | NPC1MAPTRAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1669458 | 0.77 | MEN1 (0.53) | HDAC8NPC1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | claimed |
| US-8283351-B2 | Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120219543-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISORDERS OF GLUCOSE HOMEOSTASIS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2012-08-30 | — | — | US | disclosed |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219543-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISORDERS OF GLUCOSE HOMEOSTASIS | CFTR, IAPP, GPR119 | HDAC8 3909/4885NPC1 90/4885MAPT 4663/4885 |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | CFTR, PKD1, PKD2 | HDAC8 4032/4885NPC1 228/4885MAPT 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.